HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shiseido

This article was originally published in The Rose Sheet

Executive Summary

Procter & Gamble President of Professional Care Carsten Fischer has joined Shiseido as a corporate advisor for the international businesses, effective Oct. 1, Japanese beauty company announces. Fischer joined P&G following its acquisition of the Wella Group in 2004, where he served as president of Wella Japan and exec VP for the Asia-Pacific region. "Given Mr. Fischer's impressive achievements in leading global companies, he brings to Shiseido a distinguished management know-how with business and organization-building ability, which will serve as key assets in achieving Shiseido's objectives," firm notes...

You may also be interested in...



Entries Begin To Roll In For 2024 Industry Awards

Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.

‘I Would Love To Have All The Biologic Assets’ – Formycon’s Glombitza Sets Out Portfolio Approach

In the second part of an exclusive interview, Formycon CEO Stefan Glombitza talks to Generics Bulletin about key regulatory developments in Europe and the US, the firm’s portfolio selection strategy, and upcoming milestones on the horizon.

First Off The Blocks, Fresenius Launches US Tocilizumab Biosimilar

Fresenius Kabi has kicked off competition to Genentech’s Actemra in the US, launching its Tyenne biosimilar version of tocilizumab.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014303

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel